EC
VYGR icon

EntryPoint Capital’s Voyager Therapeutics VYGR Stock Holding History

EntryPoint Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,039
Closed -$93.5K – 1669
2024
Q1 		$93.5K Sell
10,039
-10,684
-52% -$90.2K 0.08% 466
2023
Q4 		$175K Buy
+20,723
New +$150K 0.17% 128

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

EntryPoint Capital's VYGR Position: Q2 2024 in Review

EntryPoint Capital sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 10,039 shares — an estimated $93.5K sold.

EntryPoint Capital first reported a position in VYGR in Q4 2023 and held it in 2 quarters. The position peaked at $175K in Q4 2023. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • EntryPoint Capital reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 10,039 Voyager Therapeutics shares in Q2 2024, an estimated $93.5K.
  • EntryPoint Capital first reported a position in Voyager Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Voyager Therapeutics position peaked at $175K in Q4 2023.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.